Dr. Samuel Barone, MD | Chief Medical Officer
Dr. Samuel Barone is a board-certified ophthalmologist and vitreoretinal surgeon with clinical development and regulatory experience across a range of indications in ophthalmology, dermatology, rare diseases, and cell and gene therapy. Before joining Nanoscope, Dr. Barone served as chief medical officer at Gemini Therapeutics, where he oversaw the development of novel therapeutics targeting the complement system to treat genetically defined age-related macular degeneration and systemic renal disease. He has also served as chief medical officer of Veloce BioPharma and of Avalanche Biotechnologies, and senior vice president of clinical development for Adverum Biotechnologies.
Dr. Barone garnered regulatory experience as a senior medical officer at the U.S. Food and Drug Administration in the Office of Cellular, Tissue, and Gene Therapies (now Office of Therapeutic Products) and served as subject matter expert and developed guidance documents. He has global experience in overseeing clinical trials in the US as well as Australia and India.
Early in his career, he served on active duty as a flight surgeon for the United States Air Force. Dr. Barone received his M.D. from Pennsylvania State University College of Medicine and completed his residency in ophthalmology at the New York Eye and Ear Infirmary of Mount Sinai. He completed a medical and surgical retina fellowship at the University of California, San Diego.
